CTLA4 and neoplasm: The preconditioning with the anti-CTLA-4 antibody Ipilimumab was employed to increase tumor infiltration of tumor-reactive lymphocytes before tumor tissue harvest for TIL production, and data reported an increase in the success rate of ex vivo TIL expansion and an improved quality of the TIL product [37].